The project, which is part of the European Union’s Seventh Framework Programme, enjoys the participation of research institutes and centres from across Europe, and clearly reflects the EU’s interest in the discipline, which is currently undergoing expansion and development. The selection of Advancell has been viewed very positively and reflects the firm’s ability to put its technology and experience to the service of research both in the nanomedicine area and in the area of in vitro assessment. <\/p>\n
Advancell has two divisions: the Pharma division, focused on developing innovative drugs through research into new applications of already-known molecules; and the Services and Reagents division, using cell-based, in vitro techniques to assay molecules under development for their efficacy, safety and mechanism of action. The company’s business model is based on a methodology that leads to a considerable reduction in the costs, risks and development timescales of a new drug. <\/p>\n","protected":false},"excerpt":{"rendered":"
The biotech firm Advancell<\/a>, housed at the Barcelona Science Park, is the only company that will be taking part in the European NanoTEST<\/a>, project sponsored by the European Commission. The aim of the project is to develop a methodology for the systematic assessment of the potential toxicity and other health effects of nanoparticles in order to help in future drafting of specific regulations covering their use.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-45938","post","type-post","status-publish","format-standard","category-uncategorized"],"acf":[],"yoast_head":"\n